This group of patients (Rb1+, ER+) could be a target for CDK4/6 inhibition plus letrozole, with or without antiestrogen therapy, a regimen with proven efficacy in patients with advanced ER+ breast cancer [15, 16]. Here, ESR1 is linked to breast cancer.